BiBBInstruments (BIBB) Q3 2026 earnings summary

Executive summary

• EndoDrill® GI commercialization advanced with a Spanish launch alongside Palex and larger US orders from TaeWoong Medical USA; recurring sales depend on wider hospital adoption and repeat use.

• Priorities are expanding US use, building on the Spain launch, securing more European distribution partners, and preparing EndoDrill® EBUS for production and market introduction.

Financial highlights

• Q3 2026 net sales were SEK 178K vs SEK 110K; operating result was SEK -4.615M vs SEK -2.846M, and result after financial items was SEK -4.584M vs SEK -2.846M.

• 9M 2026 net sales were SEK 763K vs SEK 149K; operating result was SEK -15.045M vs SEK -9.599M, and result after financial items was SEK -15.015M vs SEK -9.539M.

• Q3 gross result was SEK -39K vs SEK 27K; 9M gross result was SEK 30K vs SEK 46K. Higher R&D costs and lower capitalization of development outlays contributed to the weaker operating result.

• Q3 R&D costs were SEK 3.116M vs SEK 1.753M; 9M R&D costs were SEK 9.963M vs SEK 5.675M.

Outlook and guidance

• Current cash is expected to fund planned operations through year-end 2027/2028; Q3 average cash burn was approximately SEK 1.8M per month.

• EndoDrill® EBUS production is planned to start in the coming months; preparations continue for a European notified-body change notification and a US FDA 510(k) submission.

• 2026 commercial priorities include increasing EndoDrill® GI use in the US, following up the Spanish launch, and establishing additional European distribution partnerships.